<!DOCTYPE html>
<html lang="en">
    <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
        <title>42</title>

        <link href="bootstrap.min.css" rel="stylesheet">
        <link href="custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="treatments.css" rel="stylesheet" type="text/css"/>
        <link href="recreated_tables.css" rel="stylesheet" type="text/css"/>
           <style>
        .sep {
            border-bottom:1px solid lightgray;
        }
        .sep td {
            padding-bottom:5px;
            padding-top:5px;
        }
        br {
            display: block;
            margin-top: 5px 0;
        }
    </style>
    </head>
    <body>
        <div class="container"><p>The predominant symptom of scabies is pruritus. Sensitization to <em>Sarcoptes scabiei</em> occurs before pruritus begins. The first time a person is infested with <em>S. scabiei</em>, sensitization takes up to several weeks to develop. However, pruritus might occur within 24 hours after a subsequent reinfestation. Scabies in adults frequently is sexually acquired, although scabies in children usually is not <sup id="fnref:856"><a class="footnote-ref" href="#fn:856" rel="footnote">1</a></sup>  <sup id="fnref:857"><a class="footnote-ref" href="#fn:857" rel="footnote">2</a></sup>.</p>
<p>Permethrin is effective, safe, and less expensive than ivermectin <sup id="fnref:858"><a class="footnote-ref" href="#fn:858" rel="footnote">3</a></sup>. One study demonstrated increased mortality among elderly, debilitated persons who received ivermectin, but this observation has not been confirmed in subsequent reports <sup id="fnref:859"><a class="footnote-ref" href="#fn:859" rel="footnote">4</a></sup>. Ivermectin has limited ovicidal activity and may not prevent recurrences of eggs at the time of treatment; therefore, a second dose of ivermectin should be administered 14 days after the first dose. Ivermectin should be taken with food because bioavailability is increased, thereby increasing penetration of the drug into the epidermis. Adjustments to ivermectin dosing are not required in patients with renal impairment, but the safety of multiple doses in patients with severe liver disease is not known.</p>
<p>Lindane is an alternative regimen because it can cause toxicity <sup id="fnref:855"><a class="footnote-ref" href="#fn:855" rel="footnote">5</a></sup>; it should only be used if the patient cannot tolerate the recommended therapies or if these therapies have failed <sup id="fnref:860"><a class="footnote-ref" href="#fn:860" rel="footnote">6</a></sup>  <sup id="fnref:861"><a class="footnote-ref" href="#fn:861" rel="footnote">7</a></sup>  <sup id="fnref:862"><a class="footnote-ref" href="#fn:862" rel="footnote">8</a></sup>. Lindane should not be used immediately after a bath or shower, and it should not be used by persons who have extensive dermatitis or children aged &lt;10 years. Seizures have occurred when lindane was applied after a bath or used by patients who had extensive dermatitis. Aplastic anemia after lindane use also has been reported. Lindane resistance has been reported in some areas of the world, including parts of the United States.</p>
<div class="footnote">
<hr />
<ol>
<li id="fn:856">
<p>Shimose L, Munoz-Price LS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep 2013;15:426–31.&#160;<a class="footnote-backref" href="#fnref:856" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:857">
<p>Monsel G, Chosidow O. Management of scabies. Skin Therapy Lett 2012;17:1–4.&#160;<a class="footnote-backref" href="#fnref:857" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
<li id="fn:858">
<p>Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010;362:717–25.&#160;<a class="footnote-backref" href="#fnref:858" rev="footnote" title="Jump back to footnote 3 in the text">&#8617;</a></p>
</li>
<li id="fn:859">
<p>Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144–5.&#160;<a class="footnote-backref" href="#fnref:859" rev="footnote" title="Jump back to footnote 4 in the text">&#8617;</a></p>
</li>
<li id="fn:855">
<p>Nolan K, Kamrath J, Levitt J. Lindane toxicity: a comprehensive review of the medical literature. Pediatr Dermatol 2012;29:141–6.&#160;<a class="footnote-backref" href="#fnref:855" rev="footnote" title="Jump back to footnote 5 in the text">&#8617;</a></p>
</li>
<li id="fn:860">
<p>Mounsey KE, Holt DC, McCarthy J, et al. Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol 2008;3:57–66.&#160;<a class="footnote-backref" href="#fnref:860" rev="footnote" title="Jump back to footnote 6 in the text">&#8617;</a></p>
</li>
<li id="fn:861">
<p>Mounsey KE, Holt DC, McCarthy JS, et al. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol 2009;145:840–1.&#160;<a class="footnote-backref" href="#fnref:861" rev="footnote" title="Jump back to footnote 7 in the text">&#8617;</a></p>
</li>
<li id="fn:862">
<p>Mounsey KE, McCarthy JS, Walton SF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol 2013;29:35–42.&#160;<a class="footnote-backref" href="#fnref:862" rev="footnote" title="Jump back to footnote 8 in the text">&#8617;</a></p>
</li>
</ol>
</div>
        </div>
            </div>
        </div>
    </body>
</html>
        